Highlights Almirall, S.A.

Equities

ALM

ES0157097017

Market Closed - BME Other stock markets 11:35:22 2024-04-29 am EDT			After market 04:00:00 pm
8.48 ^EUR	-1.05%		8.488	+0.09%

Mar. 13	Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	MT
Feb. 19	Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall: share price surges after agreement with Novo Nordisk	Feb. 19	CF
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19	MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19	CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 18	CI
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	CI
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	Dec. 12	MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	Dec. 12	CI
European Commission Approves Almirall’s Skin Disease Drug	Nov. 17	MT
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis	Nov. 17	CI
Almirall Teams Up with Absci on AI-designed Dermatological Disease Treatments	Nov. 14	MT
Absci Enters AI Drug Discovery Pact With Almirall to Develop New Therapies for Dermatological Diseases; Shares Surge Premarket	Nov. 14	MT
Almirall, S.A. Revises Earnings Guidance for the Year 2023	Nov. 09	CI
Almirall, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 08	CI
Almirall Signs Licensing Deal With EpimAb for Bispecific Antibodies Development	23-10-12	MT
Epimab Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement	23-10-12	CI
Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis	23-10-11	CI
Centrient Pharmaceuticals Joins Almirall?s Growing Innovation Hub in Barcelona	23-10-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Almirall, S.A.

Equities

ALM

ES0157097017

Highlights

Filters